This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSGN-35T
an investigational CD30-directed, next generation antibody-drug conjugate with novel tripeptide linker
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGN35T-001: Lymphomas
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources
High-level synopsis of SGN-35T and ongoing clinical trials
Detailed information about SGN-35T clinical trials
Related Links